# Autoimmune Causes of Epilepsy?

Manu Hegde, MD, PhD ECoE, VAMC-SF May 7, 2014





### **Objectives**

- 1) Understand the relationship between autoimmune encephalitides and seizures.
- 2) Understand the role of autoantibodies in "uncomplicated" epilepsy.
- 3) Understand rational approaches to autoantibody testing in the epilepsy population.

### **Case presentation**

- HPI: 47 RHM with 6 months of spells involving an unusual smell, nausea, dizziness, visual distortions, disorientation, and unresponsiveness.
- He had developed cough, dyspnea, and asthenia several months prior to spell onset, coinciding with his moving from Florida to Stockton, CA.
- PMH: Depression, remote alcohol abuse; no seizure risk factors
- Meds: Albuterol, tiotropium, B12, levetiracetam 500 mg BID
- Allergies: None
- Family Hx: No known history of epilepsy
- Social Hx: Former security alarm technician, now on disability; non-smoker, occasional alcohol, no illicits
- Neuro Exam: Normal

### **Prior Workup**

- Chest CT: axillary/mediastinal lymphadenopathy, RML treein-bud opacities
- Lung biopsy: chronic inflammation, no malignancy, mycobacterial stains neg
- Lumbar puncture: 12 WBC (88% lymphs, 11% monos), 13 RBC, Glc 55, TP 33, CSF ACE neg, cytology negative
- Serum studies:
  - Cocci Ab neg
  - HIV Ab neg
  - ACE neg
  - Galactomannan neg
  - ESR 100, CRP 7.28
- Routine EEG: normal
- Brain MRI (1.5T): normal (cervical lymphadenopathy noted)

### Interictal EEG

#### Avg reference montage

I File Edit View Navigate Protocol Format Iools Workspace Window Help		_ 8 ;
副 🎂 🎟 👕 錣 🛛 👂 150 x 🔽 🧰 🖓 🎵 ই 王 ன 🕶 🍞 🏹 🏹 🖾 中 コ タ 🔤 歸 🛠 🗐 🐰 🖬 🖬 EMU AVG old 👘 🔽 🖓 🖓 30 mm/sec	💙 26 💙 7.0 μV/m	m 🔽 70 Hz 🔽 1.000 Hz
2768 secs         Edit EEG/ho video (51:51.9)         2772 secs	Annotation	Panel ×
p1-averter and the manufacture of the manufacture of the second of the s	m	Review Video >>
7 AVe more and and a manual and and a manual and a manual manual a more a manual	Annotation D	Format <
SPI-AVennen have have been and have been and have been and have been and have been have be	spike	Montage EMU AVG old 🗸
		Timebase 30 💌 mm/sec
	Sharp Wave	Channels 26 🔽
5.AV Manun Man		Sensitivity 7.0 🔽 µV/mm
n-ave harming the many harming the second and the s	Event!!!	High Cut 🛛 🔽 Hz
Spike	Seizure	Low Cut 1.000 V Hz
3.AV. Marine Ma	m	
3.AV man have a second and the second of the	Sleep Backgro	C Frends >>
3 ave have show a show a show and a show and a sone Annon she have not a show and a she have	autra la	Time Durat Name
	Awake backgro	00:00:01 51:51 Edit E
	Edit EEG/no v	00:02:57 00:00 Fellow
p2.av on mining many many many many many many many many	m	00:05:25 00:00 Spike 00:05:26 00:00 Fellow
8.AV. many many many many many the many many many many many many many many	May Save section	00:23:42 00:00 Spike 00:23:53 00:00 Spike
sp2.avon man man man and the man	Fellow (ppota	00:25:48 00:00 Spike
4. AV and whom many many many and and the same and		00:46:11 00:00 Spike 00:51:54 01:50: Edit E
EAV - marchand and a strand and a	Prune	01:23:17 00:00 Fellow 01:29:46 00:07 Edit E
2. even has the mark of war of markers a range of mark the remaining any war to war the second and a second and	ha	01:23:50 00:00 Spike
		02·42·17 00:05 EditE .
4.AV - Mar Land Land Mar	Line	
AAV washing and a second a	mm	
4.AV mining and a share and a	herrin	
ĸ。 └┶┶╾┪┿╌┟┶╍┥┪┥╾┶┟┶╽┥╴┶┼╴╢╴╴┶╴╢┝┥╸╴┿╽┝╸╴╴┥╢╴╴╢┈╴╢╸╴╢╸╢╸╢		

#### Longitudinal bipolar montage

Reader - [4/16/1965 Henshaw, Darrel - 3/12/2013]	····						
Eile Edit View Navigate Protocol Format Iools Workspace Window Help 🗕 🗗 🗙							
🔚 🎒 🎟 👕 🎊 🔄 🕨 1 x 🔍 🖓 👘 🎝 🚦 🛃 🛃 🛨 🖓 🖓 🖄 🛱 🔶 🤛 🎝 🔍 🔛 🖓 📳 🐇 🖆 🔂 As Recorded 🛛 🔍 🖛 30 mm/sec 🔍 32 🔍 7.0 µV/n	nm 🔽 70 Hz 🔽 1.000 Hz 🎽						
	Panel   ×						
	Review Video <<						
F7-13• marchine and a second							
T3-T5• March							
T5-01• March Mar	The second						
Seizuré (00:43.3)     4 seos     July Million     Sharp Wave							
FD1-F30 minute and the manual of the second							
F3-C3• mintakan manuna manuna manuna wata wata wata wata wata wata wata wa	<b>→</b> - + 9						
C3-P30	Format <<						
p3-01. When him have have been and have been have been have been have been have been been been been been been been be	Manhana As Decended III						
FD2-F4 Mandan an many many many many many many many	Timebase 30 💉 mm/sec						
F4-C4. Marchington water and an and a second and a proper water and a proper water and an and and a proper water and a	Channels 32 💌						
C4-P4 how how he have a second and how how have have have have how how how how have have have backer of the backer of	Sensitivity 7.0 <mark>∨</mark> µV/mm						
P4-020 has in his many a many and have a first of the second and have a second and have a second and the second	High Cut 🛛 70 🛛 🖌 Hz						
	Low Cut 1.000 🕶 Hz						
En 2.58 has a demonstration of the second seco	ΰY						
	Trends >>						
	Event List <<						
	00:04:55 00:00 Fellow						
	00:05:23 00:00 Fellow						
	00:06:25 00:00 Fellow						
and the second	00:07:53 00:00 Fellow 00:07:55 00:41 Seizure						
	00:08:08 00:00 Fellow						
	00:08:39 00:00 Fellow						
SSPI-SSEMPTIME MARKEN MARKEN MARKAN	00:09:46 00:00 Fellow						
	00:10:09 00:00 Fellow 00:11:07 00:48 Seizure						
T4-C4 unalles for the second second and the second	00:11:32 00:00 Fellow						
C4-Cze manune manune manune manune and and the	00:11:55 00:00 Fellow						
GAP	<b>5</b> 00						
EKG.Ref							

🛄 Eile	e <u>E</u> dit	<u>V</u> iew <u>N</u> av	/igate	Protoco	ol Fori	<u>m</u> at <u>T</u> o	ols W <u>o</u> r	kspace	<u>W</u> indo	w <u>H</u> el	P															- 8 ×
Re	) 📾	َنَةُ 🖉 📄	1 D	1 ×	<b>~ </b>		J   ]	Ŧ	++	<b>b</b>	Y KQ	$\Box$ $\diamond$		」 <b>♀</b> │'	• 8	*	* 🖆	📑 As R	ecordeo	d 💉	- + :	30 mm/sec	✓ 32	🔽 7.0 µV/mn	n 🔽 70 H	łz 🔽 1.000 H; 🂙
$\bigcirc$	) <mark>n n</mark>		1.3	1.1				1.3		11			1:	1 1 1			0.1		1.1				1.1.1	Appotation		Panel 🗙
Fp1-F7	•		1 AN	MA	MA	h	MANAN	Maria	WWW	www	Muning	maning	mont	ma	A. A. A. A.	MARAN	www.wayara	ware a company	-	the second and all	www.	44,101,151, <b>162,4</b> 4	W. C. M. Marph	Annotacion	K Review	Video <<
F7-T3•	ĽĽ,		MAA	-	Althour	WHAN	MUMAN	nw	im	Way	with	MAN	Newwww	Mam	لبالعبرجن	MAN	1. m. A have	where when	it and	MANNAN MAR	MARY	hum Mallyn	multim	Annotation D	165X	A N
тз-т5●		u svr).	(M)	<b>W</b> alan	NA ANI	A WAY	heritelli	MMM	MANY	$\gamma_{n}$	winter	horn	have	where	illing	MUMAY	inn	Multer a shine	yu.Nerth	Ampany	with	munipula	Maria		1.00	200
T5-01•		1. Mar	NW		NAA	MAR	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	min	ñ.m	nan	han	m	har	1. AMM	Man	mond	in	mm	m	www.	him	hrm	min	Spike	A.	- ME
	il de	ive qui			7	8 se	s			0.0-		Seizure	00:48	.3)	12	secs									9 33	
Ep1-E3	. 6	UN AROUNT	he was	Antonia	nuk	aphylicial	4444	<b>n</b>	مسالمد	rim	Alman M	unn	and A	Annesan	h. A. M. Mar	Second and	wanter	the street and a	Canadiana	and the second second	and some	which the state of the	hours	Sharp Wave		
E3 C3	1.					L Million As		I LAN	a katan lini	ปแม	a hand of	l line	I nal l			ha halleda	. Hulph	التطيير بالأراسية	Unin	land a land		A Mild Miles	A deliver d		AT AL	
C2 D24	.						(in dhi			ni na	T IN AN ALL M		ALAN I				1700				in the	CAN THE REPORT		Event!!!		<b>&gt; - +</b> ৭
C3-P3•			<b>( 1 )</b>			<b>NUMBER</b>		n www.	ΥЧΥ ПРИМ Л. К. А. А	N.W.	MANA A	(MAR)	<b>I</b> MANI	N MANA	YXXX	74777	MIQUU	AM A MAN	hainal.	<b>A BHAIL</b>	dianth i	AND AND A	A NUMBER	Catalon	Format	<<
P3-01			VVV	MAAN.	vyn	, Marian Mariana di Angela di A Angela di Angela di Ang	wywaryn	<b>WWWW</b>	hun	/ WWW	NNN	VNrV	4Vu V	WWW	~VM	Invery		an a	·₩VV	proving and a	www.	www.have	VVVV	Seizure	Montage	As Recorded 🛛 🐱
•																								Sleep Backgro	Timebase	30 🗸 mm/sec
Fp2-F4	•	Allamana	العان العان	<b>,##</b> #~.!!***	ard, and the	ph/minut	rwarauphapar	Mar Marina	ner Maren	******	۵٬۵۰۹، ماروطوری	w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	noraly	where the set	hvhurv	niversation h	4.41.418-18.4	Marian water	and a gradient	ktristown of the p	<b>የቀ</b> ሎ ከለት እ	HUNKAMAN MARAN	M. Marine Marine		Channels	32 🗸
F4-C4●		TW WATER	(1994) Lak	ww	NNV	An any	nam	rlowrk,m	*****	MM/1	y why have	which when	eret the	NA WAY	140144	which the	anar watan	hite had all all an	***	*****	Not of Man	Huild Harland	MARMANIA	Awake Backgro	Sensitivitu	7.0 V uV/mm
C4-P4•		TYWW	MUMM	wyn	m	mw	nm	NWN	Jum	WM	Vitarlation	MANA	he but y	hir white a	VYA	wheeling	ALX ALX	er in the second se	****	er-mining y	(internet	*****	*****		Link Cut	70 v Ha
P4-02•		NUMAN	ww	ww	ww	m	$\sim \sim $	W	Wh	∿vriV	WW	wW	WM	MM	λŴΛΛ	hm	Nim	may	NΛΛ	www	M	rwww.W	WW	Edit EEG/no v	High Cut	
•	1																								Low Cut	1.000 🚩 Hz
Fp2-F8	•	4 March	44 war	www	vww	arrow the	www.ww	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	nam	www	when	welgentran and		en anti-	Marra Wala	manuapa	and -	munan	الهاكر الدعور ويعا	L'ordination	n <b>gra</b> tertert	whether where	thomas	Save section		<u>י</u> אַ צ
F8-T4•			Mon	unitado National	n panament	man	www.	non	mm	14/4/4	VIII MANY	(Internetion	what we	egely deglerizative	wmhhye	al when	a lation (r-1)	hter patients	WANK AN	W. Milling	where where	mentalista	WAN WAN		Trends	>
T4-T6◆	AD.		الأنادر		. Nut		1.444	h.U	ŴU.J		1.1	A M		WWW.ha		<b>Mulu</b>	Manda	h at h a	MARA .	Maluk	M.	M. M	N.A.	Fellow Annota	< Event L' Time	ist << Durat Name 🔥
T6-02•		1.			ЖA	Nuclear Street	فالمعادلة الغارة	U.M		WAN				. Jul M	MH .	. Jahk	17 <b>1</b> 14	M.A.	<u>a Kim</u>		U.M			Drupe	00:04:55	00:00 Fellow
		'' M HAL	19	W.	1	л. тр <b>і і</b>	يراطن وأنواه		1	ייי	<b>HINTE</b>	PP.	1.1.41	uddu A. I	4 ( 4)			T. <b>W</b> . A			un i	<b>ana</b> , Ana			00:05:23 00:06:13	00:00 Fellow 00:39 Seizure
C7-C3		n HUNK	UM.		de la dela			h lug /	n hik huis	فاستعاد أمدا	1 Adam	ll HA.	arrid	NUMBER	welate	hinnihai	with	and kalend	Mahah	Milling	Mah	hillingha	A Ashina A		00:06:25	00:00 Fellow
C3-T3				л <sub>и</sub> [ <del> </del> ,		l M			<b>i i i i i</b> i								1.(80)				n La				00:07:55	00:41 Seizure
T3 CO									UN		1999 A M		d da la				<u>, nutri</u>	n in the second s			11111				00:08:08 00:08:26	00:00 Fellow 00:00 Fellow
13-SSP	1 (i   _		m		ALC: N	1.01	n an triangle an triangle an triangle an triangle and tri		ባምግምሳ ለሌ ክሌ በ	100	na na vy	ሳ እ. ለ ለ		የውጥም •	N N N N	NA MA	-талар 1914 година 1914 година	and the second	TY Y	n in the		une populare Null a	W A MAN		00:08:39	00:00 Fellow
SSP1-S		M/ <b>W</b> //	Wr V	a a a a a a a a a a a a a a a a a a a	VYM	hh. M	Mr.	MVVV	INNUM	(VVV)	Winner	MAMM	"YWW	YNWM	WW	1994 V	Mary W	with	-VV-V	MAN AN	WANN	en hill printerer	<b>NO WALK</b>		00:09:46	00:00 Fellow
SSP2-T	4	The state		<b>ታ</b> ዊ አምር አካትሎች	nyay haway	مرمدهو الموصع	m	the more of	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	(internet)	1.1.1			4*************************************	V Mariana			*************	<b>44.45,163,16</b> 4	1441)11914(h)#	* <b>#</b> ***** <b>*</b> **	, in the second second	MUMARA		00:10:09 00:11:07	00:00 Fellow 00:48 Seizure
T4-C4●			r w Wie	n A HA	~h/~6*~1	n ha	non	man	www	11.44	***	MAN N	r Hahri	MANNY AND A	WYWW	<b>MANAHAN</b>	441 M				Manhak		1 N PARA 14/		00:11:32	00:00 Fellow
C4-Cz•		<b>MANANAN</b>	WW	MM	wh	when	Vilenanilar	www	NWW	VIIIV	White det (*1)	n'in this has	MWW/	NAVANA	KNY WAN	wh when		when when he had the particular the	<b>~~</b> //	waterwat	hatalant	h white the	i di kati ya		00:11:33	nn:nn Fellow
GAP		ľ					6							1											€	∋D D
EKG-Re	et <mark>HV</mark>	who have	J-	$\sim$		$\sim$	ala	$ \rightarrow $	$\sim h$	$\sim$	mm	m	+	-l-		$\neg \neg $		m	m	h-	n	-	how			

🛄 Eile	e <u>E</u> dit <u>V</u> iew <u>N</u> avigate Protocol For <u>m</u> at <u>T</u> ools Workspace <u>Wi</u> ndow <u>H</u> elp	_ = ×
8	🕽 📾 👕 🎊 🖪 🕨 1 x 🕑 🖵 🚚 📜 🗄 🕂 → → ++ 🏷 🏹 🖾 🚍 💠 🛱 🎝 🍋 🖾 🔶 📾 📓 🛠 📳 🐰 🕁 🔂 As Recorded 🛛 🗹 🖛 30 mm/sec 🕑 32 🕑 7.0 µV/m	n 🔽 70 Hz 🔽 1.000 Hz 🎽
$\bigcirc$		Panel ×
Fp1-F7	· har and a share a share with the share with the share with the share a share with the share with the share a share with the share with the share a share with the share w	Review Video <<
F7-T3♦	Michard Marken and Marken D	MA AN
T3-T5•	where we are a superior where the second and the second and the second of the second second where the second s	Y. CON
T5-01♦	hugamarian Arman municum mar maria americana an ara ana a a ana a Arma a a mariana ana a Mariana ana a Mariana ana spike	ter -ve
		A REAL
Ep1 E24		ny l
FD 004	Universities of bigs of bigs of bigs of the second s	The V
F3-C3•		<b>■ &gt; - +</b> २
C3-P3•	null durated which wild have been all the which of the start which is the heavest were rear and r	Format <<
P3-01♦	· Marile Marile Marile Marile Marile Contraction of the Contraction of the Contraction of the Contraction	Montage As Recorded 🔽
•		Timebase 30 🔻 mm/sec
Fp2-F4	• When which the and the second	Channels 32 🗸
F4-C4●	http://www.hulland.http://white.hullon.hullon.hullon.hulland.hullon	Sanailiuitu 7.0 Multima
C4-P4•	tradication when the second with the second	
P4-02◆	WWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWW	High Cut 70 🚩 Hz
		Low Cut 1.000 Mz
Fp2-F8	· Month Manun man have been and a section	٦Y
F8-T4•	How we want and the and the second and t	Trends >>
T4-T6◆	Fellow Annota Miles of Market	C Event List <<
T6-O2◆		00:04:55 00:00 Fellow
		00:05:23 00:00 Fellow 00:06:13 00:39 Seizure
CT C24	Unional with defined defined and by the last with the part of the second second of the	00:06:25 00:00 Fellow
C2 T2+		00:07:53 00:00 Fellow 00:07:55 00:41 Seizure
C3-13•		00:08:08 00:00 Fellow 00:08:26 00:00 Fellow
13-SSP1		00:08:39 00:00 Fellow
SSP1-S	ammun an Man air an	00:09:37 00:35 Seizure
SSP2-T4		00:10:09 00:00 Fellow 00:11:07 00:48 Seizure
T4-C4●		00:11:32 00:00 Fellow
C4-Cz♦	addition of the standard of th	00:12:41 00:00 Fellow
GAP		a 🗅 🗗
EKG-Re	of the hand be have been and the second of the	

Eile	Edit <u>Y</u> iew <u>N</u> avigate <u>P</u> rotocol For <u>m</u> at <u>T</u> ools Workspace <u>W</u> indow <u>H</u> elp	_ 8 :
36	🎟 👕 🎇 🖪 🕨 1 x 🔍 🖓 📮 ই 🗄 ++++ 🎔 🏹 🖾 📮 🔶 🛱 💭 😫 🛠 🗐 🐰 🕍 🚰 🖬 As Recorded 🛛 🔍 🔶 30 mm/sec 🔍 32 🔍 7.0 µV/mm	n 🔽 70 Hz 🔽 1.000 Hz
$\odot$		Panel >
p1-F7●	Mining and the second of the s	Keview Video << 100 Keview Video << 100 Keview Video K
7-T3 <b>●</b>	March	JUN ANT
3-T5 <b>◆</b>	working have a ward and a share when a share we have a share we have a share a sh	A CONTRACT
5-01•	manny much many many many many many many many many	ALC STA
	28 seos	9 3.8 N
p1-F3●	Mussienen hun marine hun	197
3-C3•	MARA mound on a man marker of the marker of the marker of the state of	
3-P3♦	An another a safe that a should be s	<b>)</b> – + ५
3-01	A A A A A A A A A A A A A A A A A A A	Format <
0-014		Montage As Recorded 👻
-2.54		Timebase 30 🔽 mm/sec
02-1 4 •		Channels 32 💌
4-04	Awake Backgro	Sensitivity 7.0 🔽 μV/mm
4-P4		High Cut 🛛 🔽 Hz
4-02●	and a share we	Low Cut 1.000 V Hz
•	Saus continu	57
p2-F8●	man was a second of the second	Trends >>
8-T4 <b>•</b>	Markey production with the production of the second s	Event List <<
4-T6 <b>◆</b>		Time Durat Name
6-02•		00:04:55 00:00 Fellow 00:05:23 00:00 Fellow
•		00:06:13 00:39 Seizure
z-C3♦	have a construction of the second of the sec	00:07:53 00:00 Fellow
3-T3 <b>●</b>		00:07:55 00:41 Seizure 00:08:08 00:00 Fellow
3-SSP1	a war and the second of the se	00:08:26 00:00 Fellow 00:08:39 00:00 Fellow
SP1-SS	enances Arabana and an and an	00:09:37 00:35 Seizure
SP2-T4	and a superior of the second o	00:09:46 00:00 Fellow 00:10:09 00:00 Fellow
4-C4 <b>●</b>	warmen he have been and he is a second of the part of	00:11:07 00:48 Seizure 00:11:32 00:00 Fellow
4-Cz●	march all and a second	00:11:55 00:00 Fellow
AP		
KG-Ref		
		1

### **3T Brain MRI**



### **Additional labs**

- Anti-NMDAR and anti-GAD65 Abs neg
- Serum HHV8 IFA neg
- Repeat HIV neg
- HBV / HCV labs neg

Anti-VGKC Ab positive (titer 850; ref range 31-88)

Now what?

### Overview

- Clinicians and scientists have long debated whether immune or inflammatory factors are important in epilepsy
- Autoimmune neurological disease is often unrelated to any particular antibody (i.e. MS)
- However, autoantibodies to neuronal antigens have been associated with a number of clinical syndromes, especially limbic encephalitides (LE), in the past decade
- These syndromes often have seizures as a prominent clinical feature

### **Overview**

- This raises several questions:
- Could autoantibodies to CNS antigens be responsible for "uncomplicated" epilepsy (seizures without classic LE symptoms)?
- What is the prevalence of such autoantibodies in the epilepsy population?
- Are the autoantibodies pathogenic?
- Are patients with these autoantibodies more likely to become medically refractory?
- Do such patients need a different approach to treatment?

### Why is this important?

#### **AEDs and Seizure Freedom:**



Kwan and Brodie, NEJM 2000

#### UCSF Pathway for Resective Surgery in Adults with Medically Refractory Focal Epilepsy



### Overview

- Efforts to define new phenotypes or subpopulations among those with "medically refractory focal epilepsy" are critical to improving treatments
- Autoantibodies are one step in this direction
  - Disclaimer: autoimmunity is more than autoantibodies!
- Antibodies to 2 targets are of particular interest:
  - N-methyl-d-aspartate (NMDA) glutamate receptor
  - Voltage-gated potassium channel complex (VGKCC)
    - LGI1
    - Caspr2

### **Prevalence** I

- Several series have studied autoantibody prevalence in epilepsy populations
- Marked differences in inclusion criteria
  - New onset vs chronic vs medically refractory
  - Age, gender
  - Selection biases ("suspected autoimmune epilepsy")
- In a study of 139 epilepsy patients McKnight et al 2005 found that 12% had VGKCC antibodies, and 4% had GAD antibodies
  - Subgroup (n=67) with medically refractory epilepsy:
    - 2: VGKCC
    - 3: GAD
    - 1: ganglioside GM1

### Prevalence II

- Majoie et al 2006: 106 women age 14-45 with long standing drug resistant epilepsy
  - 7% had + VGKC Ab
  - I patient had equivocal GAD Ab test
  - None had other autoimmune dz
- Quek et al 2012 studied 32 patients with
  - "suspected autoimmune epilepsy"
    - 91% had neuronal autoantibodies
      - 56% VGKCC
      - 22% GAD65
      - 6% CRMP
      - NMDA, Ma2, ACHR 1 patient each
    - 81% improved and 67% seizure free with immunotherapy

### Prevalence III

- Brenner et al 2013 studied cohorts with newly diagnosed and chronic focal epilepsy.
- 46/416 tested positive for serum antibodies to VGKCC (5%), glycine receptors (3%), GAD (1.7%) or NMDA receptors (1.7%)
- Significantly higher than for the controls.
- Titers significantly higher in "cryptogenic" patients
- Autoantibody+ groups: nonsignificant trend towards poor initial anticonvulsant response
- No significant difference in autoantibody prevalence between longstanding epilepsy versus recently diagnosed (argues against epiphenomenon)

### **Prevalence IV**

- Suleiman et al 2013: 12 children with suspected autoimmune epilepsy:
  - 3 NMDA receptor antibodies
  - 3 VGKC antibodies
  - 1 GAD.
- All five autoantibody-positive children improved with immunomodulatory therapy.

## Autoantibody prevalence in adult epilepsy subpopulations

Study	N	Antibody type and prevalence						
		VGKCC	NMDA-R	GAD	Other			
Brenner 2013	416	5%	1.7%	1.7%	Glycine receptor 3%			
McKnight 2005	139	12%	-	4%	<1% GM1			
Majoie 2006	106	7%	-	0	VGCC 1%			
Quek 2012	32	56%	3%	22%	CMRP 6% Ma 3% AchR 3%			

### **VGKCC** Antibodies

- VGKC critical in modulating excitability at the presynaptic terminal
- Mutations associated with benign familial neonatal seizures.
- Previously, antibodies to VGKC described, but precise antigen unclear
- Now, distinct VGKCC epitopes found with different phenotypes



### **VGKCC** Antibodies

- LGI1: extracellular matrix protein associated with the pre- synaptic potassium channel
  - Mutations seen in observed in autosomal dominant temporal lobe epilepsy with auditory features
  - Antibodies to LGI1 have also been associated with LE.
  - More recently, a novel seizure phenotype has been associated with this condition: faciobrachial dystonic seizure.
- Caspr2: antibodies more typically associated with Morvan's syndrome or neuromyotonia, +/- LE and seizures



Feature	NMDA Receptor	AMPA Receptor	GABA B Receptor	VGKCC: LGI1	VGKCC: Caspr2
Age	23 months to 76 years (median 19)	38 to 87 years (median 60)	24 to 75 years (median 62)	30 to 80 years (median 60)	46 to 77 years (median 60)
Sex	80% female	90% female	50% female	65% male	85% male
Syndrome	Psychiatric symptoms, language dysfunction, abnormal movements, seizures, decreased consciousness, breathing and autonomic instability	Classic limbic encephalitis <sup>a</sup> , isolated psychiatric symptoms	Classic limbic encephalitis, early and prominent seizures	Classic limbic encephalitis, hyponatremia (60%), brief tonic-myoclonic seizures (40%)	Encephalitis, peripheral nerve hyperexcitability, or both (Morvan syndrome)
MRI	~50% abnormal; cortical or subcortical transient increase of fluid- attenuated inversion recovery (FLAIR) signal Occasional cortical- meningeal contrast enhancement, signs of intracranial hypertension or demyelination	~90% medial temporal lobe increase of FLAIR signal	~66% medial temporal lobe increase of FLAIR signal	~84% medial temporal lobe increase of FLAIR signal	~40% with encephalitis: medial temporal lobe increase of FLAIR signal
CSF	94% abnormal <sup>b</sup> ; almost always intrathecal synthesis of antibodies	90% abnormal <sup>b</sup> ; frequent intrathecal synthesis of antibodies	90% abnormal <sup>b</sup> ; frequent intrathecal synthesis of antibodies	41% abnormal <sup>b</sup> ; infrequent intrathecal synthesis of antibodies	~25% abnormal <sup>b</sup> ; limited information regarding intrathecal synthesis of antibodies
Tumor	Age, sex, race dependent (9% to 55%) Mostly ovarian teratoma	70% tumors of the lung, breast, thymus	60% small cell lung cancer	<20% tumors (lung, thymus, other)	Limited experience, likely <20% (tumors of the thymus)

Rosenfeld and Dalmau Neuro-Onc Continuum 2012;18(2):366

### Faciobrachial Dystonic Seizures



### FBDS and LGI1 antibodies

- Irani et al 2011 found 29 patients with this syndrome
- All were positive for VGKCC antibodies
- 89% had antibodies specific for LGI1
- 77% went on to develop typical LE symptoms
- Irani et al 2013: follow-up study of 10 of these patients
- 9 were refractory to AEDs
- All had favorable response to steroids
- Outcome correlated with time to immunotherapy, but not time to AED therapy

### Anti-NMDA Receptor Encephalitis

- Seizures, neuropsychiatric disturbances, dysautonomia and choreoathetosis
- Previously, thought to be a paraneoplastic phenomenon restricted to women < 45 with ovarian teratomas.</li>
- Both genders may be affected in the absence of a detectable tumor
- Niehusmann et al 2009 studied 19 women (aged 15–45 years) with unexplained new-onset epilepsy
  - 5/19 +NMDAR ab
    - Shorter time to presentation
    - more psych sxs,
    - CSF pleocytosis,
    - extratemporal sz,
    - no mesial temporal MRI findings
    - 1/16 was paraneoplastic
- Prolonged nonconvulsive status epilepticus has also been reported in patients with anti-NMDA encephalitis

#### Clinical features of anti-NMDA receptor encephalitis

#### Two stages:

Early: neuropsychiatric sx (psychosis, behavior change, amnesia, dysphasia), seizures in 70% Late: dyskinesias, altered consciousness, dysautonomia, central hypoventilation

#### Tumor association:

Paraneoplastic in 38% (46% of women, 6% of men), usu. ovarian teratoma (94%)

#### Diagnostic workup:

Clinical syndrome, MRI, EEG, serum and CSF (intrathecal Ab production) for anti-NMDAR Ab





Irani et al. Brain (2010) & Titulaer et al. Lancet Neurol (2013)

#### Potential pathogenic mechanisms of anti-NMDAR Ab's



Rao and Finkbeiner, TINS (2007)





Pre 6000

#### Dalmau et al, *Lancet Neurol* (2011)

#### Channel conformation (hyperfunction)

NMDAR internalization (hypofunction)



#### Immunosuppressive treatment for anti-NMDAR encephaliitis

Tumor removal (if applicable)

First-line immunosuppression – IV Ig, corticosteroids, PLEX Second-line immunosuppression – rituximab, cyclophosphamide



#### Prognosis

75% recover (reverse order of symptom onset); 25% death / severe disability Patients without tumors need 2<sup>nd</sup>-line immunotherapy more often but have similar recovery Early treatment predicts better recovery, which can be protracted (<24 months)

Dalmau Lancet Neurol (2011) & Titulaer et al. Lancet Neurol (2013)

### Anti-GABA<sub>A</sub> Receptor Encephalitis

HOT OFF THE PRESSES!

### Anti-GABA<sub>A</sub> Receptor Encephalitis

- Petit Pedrol et al, 2014 studied serum and CSF from 140 patients with encephalitis, seizures or status epilepticus, and antibodies to unknown neuropil antigens
- 6/140 had high titers of antibodies to the GABAA receptor
- Another 12 had low titers
- Clinical presentation ranged from seizures alone (rarely) to a typical limbic encephalitis picture
- Some had features of Stiff-Person or Opsoclonus-Myoclonus syndromes
- 12/15 responded to a mix of AED and immunomodulatory therapies; 3 died

### The scant evidence club

Molecule	Role	Notes
Anti-AMPA receptor antibodies	Produces LE with prominent seizures	Few case series
Anti-GABA <sub>B</sub> receptor antibodies	RPD or LE with prominent seizures	Few (one?) case series
Anti-GAD antibodies	Seen in epilepsy patients, but also seen in IDDM, Stiff Person syndrome.	Intracellular, nonspecific, unlikely to be pathogenic. However, might be associated with lower cortical GABA levels in epilepsy patients (MRS data; Stagg et al 2010)
CRMP antibodies Antineuronal antibody type		

VGCC antibodies Ganglionic achR antibodies

## EVEN HOTTER OFF THE PRESSES! Treatment

- Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy
- Class IV evidence
- Inclusion:
  - Presence of at least 1 neural autoantibody (n=23) OR
  - Personal or family history or physical stigmata of autoimmunity AND
  - Frequent or medically intractable seizures
- Treatment: 6-12 weeks of IV methylprednisolone or IVIg
- Retrospective categorizations of seizure frequency
  - Daily, weekly, monthly

Figure 1 Clinical features suggestive of autoimmune epilepsy

- Acute to subacute onset (maximal seizure frequency ≤ 3 months)
- Multiple seizure types or faciobrachial dystonic seizures
- AED resistance
- Personal or family history (1<sup>st</sup> degree relative) of autoimmunity
- History of recent or past neoplasia
- Viral prodrome
- Evidence of CNS inflammation
  - CSF (elevated protein, pleocytosis, oligoclonal bands, + CSF index)
  - MRI (mesial temporal or parenchymal T2 hyperintensity)
  - Hypermetabolism on functional imaging (PET)
- Detection of neural autoantibody

AED = antiepileptic drug.

 Identified 29 patients in Mayo autoimmune neurology clinic with a chief complaint of seizures

Antibody	Ν	Responders
VGKCC	12	12
gAChR	3	2
CC P/Q	1	0
GAD65	6	2
Ma1/Ma2	1	0
None	6	2

- 62% favorable response
  - 10/18 -> seizure free
  - Remainder had >50% reduction in seizure frequency
- Half of initial non-responders responded to second immunotherapy agent
- All remained on AEDs
- 89% of responders took long-term maintenance immunotherapy



### So, who should we test?

- We need large prospective observational studies to determine true autoantibody prevalence, prognostic value (regarding drug resistance), and to determine risk factors for autoantibody presence
- In the absence of such data, consider testing patients in which some elements of the anti-VGKCC or anti-NMDA syndrome are present to suggest high pretest probability
- Additional factors that may influence your decision include:
  - Younger women or older men
  - Explosive onset, frequent seizures, multiple seizure types
  - Medically refractory
  - Family or personal autoimmune history
  - Hyponatremia, SIADH, prominent neuropsychiatric sxs, cerebellar signs, or movement disorder
  - Medically refractory, poor surgical candidacy
- LP for CSF may be a useful screening tool if unsure

Back to our case...

### Whole-body PET-CT



### **Cervical Lymph Node Biopsy**



N.B. images not from patient, c.f. Schulte and Talat (2010) Nat Rev Clin Oncol

Histology: nodular pattern of 'onion-skinned' follicles, abundance of interfollicular CD138+ plasma cells, no lymphoma, HHV8 stain negative

Flow cytometry: no clonal lymphoid populations

Dx: Multicentric Castleman's Disease, plasma cell variant

### **Castleman's Disease**

- Angiofollicular lymph node hyperplasia: Rare lymphoproliferative disorder with increased risk of lymphoma; unicentric (UCD) and multicentric (MCD) forms; UCD associated with paraneoplastic pemphigus; MCD often associated with HIV and HHV8
- Clinical:
- UCD: young adult, often asymptomatic, mass can cause compression sx
- -MCD: middle-aged patient, non-specific 'B' symptoms, peripheral lymphadenopathy, cough/dyspnea related to pulmonary infiltrates
- Diagnosis: imaging, labs (anemia, hypoalbuminemia, ↑ESR), lymph node bx (pathology: hyaline vascular variant (90%), plasma cell variant, mixed)
- Treatment:
- Resection curative in unicentric disease and prognosis favorable
- -MCD is more aggressive, course variable but prognosis usu. worse (median survival 8-14 mo); rituximab first-line, chemo if fails (etoposide vs. CHOP)
- Significance:
- <15 reported cases of CD with CNS involvement (all UCD with mass lesions, MRI similar to meningiomas), 8 patients had seizures
- Paraneoplastic limbic encephalitis has been rarely reported with malignant hemopathies (AML, HL, NHL), sometimes with anti-VGKC Ab's, but no reports in Castleman's

### Follow-up

Seizures well-controlled on Depakote XR 1000 mg BID

Rituximab treatment initiated

Plan to follow with serial PET-CT and anti-VGKC Ab titers

### Conclusions

- Think about autoantibody testing in patients with new-onset refractory focal epilepsy without a clear etiology
- Antibodies to the VGKCC, NMDA receptor, and possibly GABA<sub>A</sub> receptor are likely highest-yield
- The full spectrum of these phenotypes is not yet known
- More data is needed to determine autoantibodies' prognostic significance in epilepsy
- A number of other immune/inflammatory mediators are under active investigation for their roles in epilepsy

### Acknowledgments

- Vikram Rao, MD PhD
- Sarah Shalev, MD
- Siddharth Kharkar, MD
- Yana Kriseman, MD
- Susannah Cornes, MD
- Nina Garga, MD
- Karen Parko, MD
- Sarosh Irani, MD, DPhil

### References

- Brenner et al, Epilepsia 54, 1028–1035 (2013).
- Hegde & Lowenstein, Biomarkers Med. 8(3), 413–427 (2014)
- Irani et al, Ann. Neurol. 69(5), 892–900 (2011).
- Irani et al, Brain. 2013 Oct;136(Pt 10):3151-62
- McKnight et al, Neurology 65(11), 1730–1736 (2005).
- Niehusmann et al, Arch. Neurol. 66(4), 458–464 (2009).
- Petit-Pedrol et al, Lancet Neurol 2014; 13: 276–86
- Quek et al, Arch. Neurol. 69(5), 582 (2012).
- Suleiman et al. Epilepsia 54(6),1036–1045 (2013)
- Toledano et al. Neurology, published online April 4, 2014